MedTrace Logo

Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration

NCT02157077 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-12-06

No results posted yet for this study

Summary

The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis.

The regimen proposed for this study is the 3 monthly injection followed by a 6 weeks interval injection until week 26.

Conditions

  • Macular Degeneration
  • Wet Macular Degeneration
  • Retinal Degeneration
  • Retinal Diseases
  • Eye Diseases

Interventions

DRUG

Aflibercept

Intravitreal Injection

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Centre Hospitalier Intercommunal Creteil

    lead OTHER

Principal Investigators

  • Eric Souied, MD · Centre Hospitalier Intersommunal de Créteil

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02157077 on ClinicalTrials.gov